Table 5:
Treatment failure rates (per protocol population)
| Timing of visits | Treatment group, n0. (%)* | p-value | |
|---|---|---|---|
|
CT participants (n = 172 ) |
Non-CT participants (n = 119 ) |
||
| Overall, n0. (%;95 % CI) | 29 (19.0; 13.1–26.1) | 10 (8.6; 4.2–15.3) | 0.017 |
| By visit† | |||
| EOT | 10 (7.5) | 7 (6.3) | |
| SVR12 | 5 (4.1) | 2 (2.6) | |
| SVR24 | 3 (3.3) | 1 (2.0) | |
| 6 mo post-SVR | 7 (10.1) | 0 (0.0) | |
| 12 mo post-SVR | 2 (4.0) | 0 (0.0) | |
| 18 mo post-SVR | 1 (2.5) | 0 (0.0) | |
| 24 mo post-SVR | 1 (5.3) | 0 (0.0) | |
* Unless otherwise indicated
† Proportions based on patients with available data at each visit
CT = Core transmitter; EOT = End of treatment; SVR = Sustained virologic response